LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline

Abstract EN

Background.

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor for oxidized low-density lipoprotein (Ox-LDL) in the aorta of aged rats.

Ox-LDL initiates LOX-1 activation in the endothelium of lipid-accumulating sites of both animal and human subjects of hypercholesterolemia.

Targeting LOX-1 may provide a novel diagnostic strategy towards hypercholesterolemia and vascular diseases.

Hypothesis.

This study was planned to address whether aegeline (AG) could bind to LOX-1 with a higher affinity and modulate the uptake of Ox-LDL in hypercholesterolemia.

Study Design.

Thirty-six Wistar rats were divided into six groups.

The pathology group rats were fed with high-cholesterol diet (HCD) for 45 days, and the treatment group rats were fed with HCD and aegeline/atorvastatin (AV) for the last 30 days.

In vivo and in vitro experiments were carried out to assay the markers of atherosclerosis like Ox-LDL and LOX-1 levels.

Histopathological examination was performed.

Oil Red O staining was carried out in the IC-21 cell line.

Docking studies were performed.

Results.

AG administration effectively brought down the lipid levels induced by HCD.

The lowered levels of Ox-LDL and LOX-1 in AG-administered rats deem it to be a potent antihypercholesterolemic agent.

Compared to AV, AG had a pronounced effect in downregulating the expression of lipids evidenced by Oil Red O staining.

AG binds with LOX-1 at a higher affinity validated by docking.

Conclusion.

This study validates AG to be an effective stratagem in bringing down the lipid stress induced by HCD and can be deemed as an antihypercholesterolemic agent.